Compare STMicroelectronics NV (STM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs 10X Genomics Inc — how do they compare? STMicroelectronics NV trades at $53.75 (market cap $50.29B), while 10X Genomics Inc trades at $80 (market cap $9.92B). The key difference: STMicroelectronics NV is far larger — about 5.1× 10X Genomics Inc's market cap, and STMicroelectronics NV pays a 0.64% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold STMicroelectronics NV for 66 Days and 10X Genomics Inc for 92 Days on average.
| STM | TXG | |
|---|---|---|
Market Cap | $50.29B | $9.92B |
Volume | 9,536,788 | 9,372,166 |
Sector | Technology | Health |
52-Week High | $79.91 | $97.74 |
52-Week Low | $21.20 | $11.48 |
Typical Hold Time | 66 Days | 92 Days |
Enterprise Value | $47.81B | $9.44B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM (STMicroelectronics) trades at $52.71, down 10.24% in the last session. The stock shows a bullish technical signal with moving averages supporting an uptrend, though oscillators are neutral. Fundamentally, revenue declined to $11.80B in 2025 with a net income margin of -0.39%, but recent Q2 2026 earnings beat expectations. Analyst sentiment is positive with a consensus price target of $77.31. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2B by 2027.
The outlook for STM hinges on execution in AI and automotive segments, offering growth potential, but risks include margin pressures from fab transitions and competitive threats. Wall Street's buy rating majority (51.72%) reflects optimism, though investors should monitor earnings consistency and debt levels, with the stock trading below consensus target indicating potential upside if recovery sustains.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
